~~<i id='3DDDF867B4'><strike id='3DDDF867B4'><tt id='3DDDF867B4'><pre id='3DDDF867B4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：Wikipedia 2025-09-03 14:37:54 - browse：62

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

focus

RubyWallauforSTATSareptaTherapeuticssaidMondayafternoonthatitsgenetherapyforDuchennemusculardystroph

WSS

Prime Medicine says its gene editing passes test in monkeys

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Federal judge rules Oregon’s tough new gun law is constitutional

After Sarepta trial failure, Duchenne families brace for more debate

Argenx drug significantly slows progression of nerve disorder

J&J expands global access to TB drug amid advocacy campaign

focus

Wikipedia

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

BioMarin wins approval for gene therapy to treat hemophilia A

Federal judge rules Oregon’s tough new gun law is constitutional

Bright Health sells Medicare Advantage business to Molina

Life sciences investors close nearly $6 billion in new funds

Supreme Court strikes down use of affirmative action

Prime Medicine says its gene editing passes test in monkeys

Drug repurposing or repositioning? The language matters

Medicare proceeds with plan to claw back hospital funds

hotspot

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

After Sarepta trial failure, Duchenne families brace for more debate

Medicare must police algorithms in Medicare Advantage, Dems say

Explaining an after

Care demand spikes challenge UnitedHealth’s provider arm

Involuntary treatment for addiction doesn't work

hotspot

hotspot

focus

focus